A synthetic peptide for use as a blocking control in assays to test for specificity of ABAT antibody, Alternative Names: ABAT control peptide, ABAT antibody Blocking Peptide, Anti-ABAT Blocking Peptide, 4-Aminobutyrate Aminotransferase Blocking Peptide, GABA-AT Blocking Peptide, GABAT Blocking Peptide, NPD009 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
ABAT
(4-Aminobutyrate Aminotransferase (ABAT))
Hintergrund
4-aminobutyrate aminotransferase (ABAT) is responsible for catabolism of gamma-aminobutyric acid (GABA), an important, mostly inhibitory neurotransmitter in the central nervous system, into succinic semialdehyde. The active enzyme is a homodimer of 50 kDa subunits complexed to pyridoxal-5-phosphate. ABAT in liver and brain is controlled by 2 codominant alleles with a frequency in a Caucasian population of 0.56 and 0.44. The ABAT deficiency phenotype includes psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and EEG abnormalities.4-aminobutyrate aminotransferase (ABAT) is responsible for catabolism of gamma-aminobutyric acid (GABA), an important, mostly inhibitory neurotransmitter in the central nervous system, into succinic semialdehyde.